3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 1/2
1
Status
Completed
4
Sponsor Class
INDUSTRY
3
OTHER
1
Study Type
Interventional
4
Sponsor
Cancer Type
Gastrointestinal
3
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrent Platinum Resistant Ovarian Cancer
1
Rectal Neoplasms
1
Neoplasm Metastasis
1
Carcinoma
1
Adenoviridae Infections
1
Interventions
Cyclophosphamide
1492
Cisplatin
1414
Paclitaxel
1317
Radiotherapy
1261
Carboplatin
1250
Gemcitabine
1215
Docetaxel
1109
Bevacizumab
1030
Fluorouracil
894
Doxorubicin
792
Dexamethasone
748
Rituximab
719
Capecitabine
716
Oxaliplatin
700
pembrolizumab
680
Etoposide
678
Irinotecan
634
Filgrastim
621
Cytarabine
586
Leucovorin
579
Nivolumab
558
Vincristine
515
Prednisone
475
Cetuximab
465
Bortezomib
459
Erlotinib Hydrochloride
456
Trastuzumab
447
Methotrexate
438
Lenalidomide
427
Pemetrexed
420
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Completed
×
Interventional
×
enadenotucirev
×
Clear all
NCT03916510
2025-02-06
CEDAR
University of Oxford
Phase 1
Completed
12 enrolled
13 charts
NCT02636036
2021-11-09
SPICE
Akamis Bio
Phase 1
Completed
51 enrolled
NCT02028117
2021-05-13
OCTAVE
Akamis Bio
Phase 1
Completed
38 enrolled
NCT02028442
2020-03-12
EVOLVE
Akamis Bio
Phase 1/2
Completed
61 enrolled